Uterine Anomalies disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: UTR058 MIFTS: 53	Uterine Anomalies Categories: Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Uterine Anomalies

MalaCards integrated aliases for Uterine Anomalies:

Name: Uterine Anomalies ⁵⁷

Uterine Diseases ⁵³ ⁴¹ ⁴³ ⁷¹

Uterine Disease ¹¹ ¹⁴

Uterine Abnormality ⁵³

Uterine ⁷⁵

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the genitourinary system

Noninflammatory disorders of female genital tract

Other noninflammatory disorders of uterus, except cervix

Noninflammatory disorder of uterus, unspecified

External Ids:

Disease Ontology ¹¹ DOID:345

OMIM® ⁵⁷ 192000

ICD9CM ³⁴ 621.9

MeSH ⁴³ D014591

NCIt ⁴⁹ C26907

SNOMED-CT ⁶⁸ 237068005

ICD10 ³¹ N85.9

MedGen ⁴⁰ C0266383

SNOMED-CT via HPO ⁶⁹ 31401003

UMLS ⁷¹ C0042131

Sources

Summaries for Uterine Anomalies

MedlinePlus: ⁴¹ The uterus, or womb, is the place where a baby grows when a woman is pregnant. The first sign of a problem with the uterus may be bleeding between periods or after sex. Causes can include hormones, thyroid problems, fibroids, polyps, cancer, infection, or pregnancy. Treatment depends on the cause. Sometimes birth control pills treat hormonal imbalances. If a thyroid problem is the cause, treating it may also stop the bleeding. If you have cancer or hyperplasia, an overgrowth of normal cells in the uterus, you may need surgery. With two other uterine problems, tissue that normally lines the uterus grows where it is not supposed to. In endometriosis, it grows outside the uterus. In adenomyosis, it grows in the uterus's outside walls. Pain medicine may help. Other treatments include hormones and surgery.

MalaCards based summary: Uterine Anomalies, also known as uterine diseases, is related to uterine sarcoma and uterine corpus cancer, and has symptoms including pelvic pain An important gene associated with Uterine Anomalies is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Interactions between immune cells and microRNAs in tumor microenvironment. The drugs Doxycycline and Ergometrine have been mentioned in the context of this disorder. Affiliated tissues include uterus, cervix and lymph node, and related phenotype is bicornuate uterus.

Disease Ontology: ¹¹ A female reproductive system disease that is located in the uterus.

More information from OMIM: 192000

Sources

Related Diseases for Uterine Anomalies

Diseases in the Uterine Anomalies family:

Uterine Inflammatory Disease

Diseases related to Uterine Anomalies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2132)

#	Related Disease	Score	Top Affiliating Genes
1	uterine sarcoma	33.1	ESR1 CYP19A1
2	uterine corpus cancer	32.9	MIR139 H2AC18 ESR1
3	endometrial stromal sarcoma	32.3	H2AC18 ESR1 CYP19A1
4	uterine benign neoplasm	32.3	MIR199A1 ESR1 CYP19A1
5	cervix disease	32.2	MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
6	endometrial disease	32.2	MIR200A MIR141 ESR1
7	placenta disease	32.0	MIR518D MIR199A1 H2AC18
8	cervix carcinoma	32.0	MIR9-1 MIR214 MIR21 MIR200A MIR199A1 MIR196A1
9	breast cancer	31.5	MIR9-1 MIR34A MIR214 MIR21 MIR200A MIR199A1
10	renal cell carcinoma, nonpapillary	31.5	MIR9-1 MIR361 MIR34A MIR214 MIR21 MIR200A
11	lymphoma, hodgkin, classic	31.4	MIR9-1 MIR21 MIR200A H2AC18
12	diffuse large b-cell lymphoma	31.4	MIR9-1 MIR214 MIR21 MIR199A1 MIR196A1 MIR17
13	hypertension, essential	31.3	MIR9-1 MIR518D MIR361 MIR34A MIR214 MIR21
14	vascular disease	31.3	MIR214 MIR21 MIR199A1 MIR145 MIR143 ESR1
15	ovarian disease	31.3	MIR9-1 MIR518A1 MIR34A MIR214 MIR21 MIR200A
16	lynch syndrome	31.3	MIR17 MIR139 H2AC18 ESR1
17	kidney cancer	31.3	MIR214 MIR21 MIR199A1 MIR17 MIR145 MIR142
18	lymphoma, non-hodgkin, familial	31.2	MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
19	rectum cancer	31.2	MIR214 MIR21 MIR200A MIR17 MIR145 MIR143
20	human papillomavirus infectious disease	31.1	MIR21 MIR199A1 MIR196A1 MIR142 MIR139
21	leukemia, acute myeloid	31.1	MIR9-1 MIR361 MIR34A MIR21 MIR199A1 MIR196A1
22	gastrointestinal stromal tumor	31.1	MIR518A1 MIR199A1 H2AC18 ESR1
23	kidney disease	31.1	MIR21 MIR200A MIR199A1 MIR141 HNF1B ESR1
24	rectal benign neoplasm	31.1	MIR17 MIR145 MIR143
25	endometriosis of ovary	31.1	MIR9-1 MIR199A1 MIR145 MIR141 MIR139 HNF1B
26	ewing sarcoma	31.1	MIR9-1 MIR214 MIR199A1 H2AC18
27	immune deficiency disease	31.1	MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
28	ovarian serous carcinoma	31.1	MIR214 MIR21 MIR200A MIR199A1 MIR145 MIR143
29	bladder cancer	31.1	MIR21 MIR200A MIR199A1 MIR17 MIR145 MIR143
30	type 2 diabetes mellitus	31.0	MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
31	gastric cancer	31.0	MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
32	leukemia, acute lymphoblastic	31.0	MIR9-1 MIR214 MIR21 MIR199A1 MIR196A1 MIR17
33	body mass index quantitative trait locus 11	31.0	MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
34	endometriosis	30.9	MIR200A MIR199A1 MIR17 MIR145 MIR143 MIR142
35	peripheral nervous system disease	30.9	MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
36	connective tissue disease	30.9	MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
37	cervix small cell carcinoma	30.9	MIR199A1 MIR145 MIR143
38	skin melanoma	30.9	MIR21 MIR200A MIR199A1 H2AC18
39	respiratory failure	30.9	MIR21 MIR199A1 MIR17 MIR142 H2AC18
40	ovarian clear cell carcinoma	30.9	MIR9-1 MIR21 MIR199A1 HNF1B H2AC18
41	lung cancer susceptibility 3	30.9	MIR9-1 MIR214 MIR21 MIR200A MIR199A1 MIR196A1
42	lung cancer	30.8	MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21
43	lipid metabolism disorder	30.8	MIR21 MIR199A1 MIR17 H2AC18
44	lymphatic system disease	30.8	MIR9-1 MIR518A1 MIR34A MIR214 MIR21 MIR199A1
45	hematologic cancer	30.8	MIR9-1 MIR518A1 MIR34A MIR214 MIR21 MIR199A1
46	ovary adenocarcinoma	30.8	MIR196A1 MIR17 H2AC18 ESR1
47	lymphangioma	30.7	MIR200A MIR199A1 MIR143 H2AC18
48	leukemia, chronic lymphocytic	30.7	MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR196A1
49	esophageal cancer	30.7	MIR9-1 MIR361 MIR34A MIR214 MIR21 MIR200A
50	myelodysplastic syndrome	30.7	MIR9-1 MIR34A MIR199A1 MIR17 MIR142 H2AC18

Graphical network of the top 20 diseases related to Uterine Anomalies:

Sources

Symptoms & Phenotypes for Uterine Anomalies

Human phenotypes related to Uterine Anomalies:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	bicornuate uterus ³⁰			HP:0000813

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

G U:
uterine anomalies
uterus arcuatus
uterus bicornis unicollis

Clinical features from OMIM®:

192000 (Updated 08-Dec-2022)

UMLS symptoms related to Uterine Anomalies:

pelvic pain

Sources

Drugs & Therapeutics for Uterine Anomalies

Drugs for Uterine Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 599)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

Ergometrine

Approved

Phase 4

60-79-7

443884

Azithromycin

Approved

Phase 4

83905-01-5

447043

Lymecycline

Approved, Investigational

Phase 4

992-21-2

Tetracycline

Approved, Vet_approved, Withdrawn

Phase 4

60-54-8

5353990

Letrozole

Approved, Investigational

Phase 4

112809-51-5

3902

Dydrogesterone

Approved, Investigational, Withdrawn

Phase 4

152-62-5

9051

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Cetrorelix

Approved, Investigational

Phase 4

120287-85-6

25074887

Ferrous fumarate

Approved

Phase 4

141-01-5

Flurbiprofen

Approved, Investigational

Phase 4

5104-49-4

3394

Racephedrine

Approved, Experimental

Phase 4

299-42-3, 90-82-4, 90-81-3

5032 9294 7028

Phenylephrine

Approved

Phase 4

59-42-7

6041

Oxymetazoline

Approved, Investigational

Phase 4

1491-59-4

4636

Tranexamic acid

Approved

Phase 4

1197-18-8

5526

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Mecobalamin

Approved, Investigational

Phase 4

13422-55-4

Zinc oxide

Approved

Phase 4

1314-13-2

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

Mefenamic acid

Approved

Phase 4

61-68-7

4044

Butorphanol

Approved, Illicit, Vet_approved

Phase 4

58786-99-5, 42408-82-2

5361092

Plasminogen

Approved

Phase 4

9001-91-6

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Chloroprocaine

Approved, Investigational

Phase 4

133-16-4

8612

Naproxen

Approved, Vet_approved

Phase 4

22204-53-1

156391 1302

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Mepivacaine

Approved, Vet_approved

Phase 4

96-88-8, 1722-62-9

4062

Norethisterone

Approved

Phase 4

68-22-4

199472 6230

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Iron

Approved

Phase 4

7439-89-6

29936

Anastrozole

Approved, Investigational

Phase 4

120511-73-1

2187

Indomethacin

Approved, Investigational

Phase 4

53-86-1

3715

Cefazolin

Approved

Phase 4

25953-19-9

33255

Prilocaine

Approved

Phase 4

721-50-6

4906

Methylergometrine

Approved

Phase 4

113-42-8

8226

Carboprost tromethamine

Approved

Phase 4

58551-69-2

35023177

Dinoprost tromethamine

Approved, Vet_approved

Phase 4

38562-01-5

Dinoprost

Approved, Investigational

Phase 4

551-11-1

5283078 5280363

Medroxyprogesterone acetate

Approved, Investigational

Phase 4

520-85-4, 71-58-9

6279 10631

Ethinylestradiol

Approved

Phase 4

57-63-6

5991

Desogestrel

Approved

Phase 4

54024-22-5

40973

Goserelin

Approved

Phase 4

65807-02-5

5311128 47725

Dienogest

Approved

Phase 4

65928-58-7

13175121 68861

Celecoxib

Approved, Investigational

Phase 4

169590-42-5

2662

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Interventional clinical trials:

(show top 50) (show all 2750)

#	Name	Status	NCT ID	Phase	Drugs
1	Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion	Unknown status	NCT02868437	Phase 4
2	Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section. Controlled Comparative Study.	Unknown status	NCT02279628	Phase 4	Ropivacaine;Morphine
3	Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy , a Randomized Control Trail	Unknown status	NCT02643186	Phase 4	preoperative vaginal misoprostol
4	Multicenter Randomized Clinical Trial to Evaluate the Safety and Effectiveness of Cavaterm TM Thermal Balloon Endometrial Ablation in Women With Dysfunctional Uterine Bleeding Compared to Transcervical Resection of the Endometrium (TCRE)	Unknown status	NCT00549159	Phase 4
5	PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment	Unknown status	NCT00378729	Phase 4	Metformin and FSHr
6	Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth in Pregnant Women With a Uterine Cervix Measuring 25 mm or Less in Length	Unknown status	NCT02511574	Phase 4	natural progesterone
7	Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2	Unknown status	NCT02357563	Phase 4	ulipristal acetate;Leuprolide acetate
8	Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant Using Norethisterone (NET)-Only Pill: a Randomized Controlled Trial	Unknown status	NCT04047875	Phase 4	Norethisterone 10mg/day;Placebo
9	Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma	Unknown status	NCT02361879	Phase 4	ulipristal acetate;Leuprolide acetate
10	Comparing Oxytocin and Oxytocin-ergometrine Combinations for Increasing Uterine Tone in Cesarean Delivery: a Pharmacokinetic-pharmacodynamic Study.	Unknown status	NCT01236482	Phase 4	Oxytocin versus oxytocin-ergometrine
11	Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study	Unknown status	NCT01239641	Phase 4
12	ED90 Determination of Carbetocin for the Prevention of Postpartum Uterine Atony in Women Undergoing an Elective Cesarean Delivery	Unknown status	NCT01579201	Phase 4	Carbetocin
13	A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy	Unknown status	NCT03815344	Phase 4	Standard;Standard-vaginal misoprostol
14	Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women	Unknown status	NCT02440750	Phase 4	Dienogest;Ulipristal acetate
15	Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia?	Unknown status	NCT00842738	Phase 4
16	A Randomized Controlled Trial Study, To Compare Colporrhaphy Versus NAZCA TC™ ,Macroporous Polypropylene Mesh, In Surgical Treatment To Greater Anterior Vaginal Prolapse .	Unknown status	NCT00676325	Phase 4
17	A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer	Unknown status	NCT02629510	Phase 4	Tachosil
18	A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer	Unknown status	NCT03206684	Phase 4	PEG-rhG-CSF;rhG-CSF
19	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	Unknown status	NCT01021904	Phase 4
20	Study of Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Antibiotic Treatment	Unknown status	NCT01661985	Phase 4	Azithromycin;Doxycycline;lymecycline
21	Randomized Double-blind Placebo Controlled Trial to Assess the Role of Intrauterine Cornual Block (ICOB) in Combination With Direct Cervical Block in Outpatient Endometrial Ablation	Completed	NCT01808898	Phase 4
22	Ulipristal Acetate Therapy Versus Uterine Artery Embolization in Management of Uterine Fibroids	Completed	NCT04832906	Phase 4	Ulipristal Oral Tablet
23	A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)	Completed	NCT00628901	Phase 4
24	The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids	Completed	NCT00995878	Phase 4
25	A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study.	Completed	NCT01492179	Phase 4	Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
26	A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates.	Completed	NCT01953107	Phase 4
27	Efficacy and Safety of Different Doses of Vaginal Misoprostol Prior to Intra Uterine Contraceptive Device Insertion	Completed	NCT04273984	Phase 4	Misoprostol
28	Randomized Controlled Trial of IV Nitroglycerin in Cesarean Deliveries After Second Stage Arrest for the Prevention of Uterine Extension	Completed	NCT02265965	Phase 4	intravenous nitroglycerin
29	Phase IV Study of Flurbiprofen Axetil for Uterine Contraction Pain After Abortion	Completed	NCT00725218	Phase 4	Saline;Flurbiprofen Axetil
30	Study of Special Guided Training Model on Insertion Techniques for Postplacental Intra Uterine Device to Prevent Expulsion	Completed	NCT02054195	Phase 4
31	Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study	Completed	NCT02293447	Phase 4	Lidocaine per-embolization;Lidocaine post-embolization
32	Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.	Completed	NCT00746031	Phase 4	GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
33	Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section	Completed	NCT02780245	Phase 4	Tranexamic Acid
34	Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy	Completed	NCT02620345	Phase 4	Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
35	Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery	Completed	NCT00785395	Phase 4	Oxytocin infusion
36	Efficacy of Magnesium and Alpha Lipoic Acid Supplementation in Reducing Premature Uterine Contractions	Completed	NCT02016495	Phase 4	Placebo
37	Buffered Lidocaine for Paracervical Block to Decrease Injection Pain During First Trimester Uterine Aspirations	Completed	NCT03107754	Phase 4	Lidocaine;Lidocaine-Sodium Bicarbonate
38	Pain Perception and Side Effects During Sonohysterography With Balloon Catheters: a Randomized Comparative Study of Cervical With Uterine Catheter Placement	Completed	NCT01936116	Phase 4
39	A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women	Completed	NCT03886220	Phase 4	Elagolix;Placebo
40	Propofol-butorphanol Combined Anesthesia During Uterine Curettage on Abortion	Completed	NCT00795314	Phase 4	Fentanyl Citrate;Butorphanol Tartrate
41	A Prospective, Randomized, Single Blind, Two Arms Controlled Study to Confirm the Safety and Verify Performance of the IUB™ SCu300A Intrauterine Device in Comparison to TCu380 IUD Intra-uterine Contraceptive Device	Completed	NCT02036177	Phase 4
42	A Multicentre, Open Label, Uncontrolled Study of the Tolerance, Acceptability and Contraceptive Efficacy of Mirena 52 mg®, an Intra-uterine Levonorgestrel Device, During the First Year After Insertion Post-partum	Completed	NCT00696202	Phase 4	Mirena (BAY86-5028)
43	Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids	Completed	NCT03317795	Phase 4	Levonorgestrel IUS;Tranexamic Acid
44	Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery	Completed	NCT00790062	Phase 4	Oxytocin
45	Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids	Completed	NCT00159328	Phase 4
46	Intra-uterine Injection of Human Chorionic Gonadotrophin Before Embryo Transfer in ICSI	Completed	NCT01030393	Phase 4	human chorionic gonadotrophin
47	Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial	Completed	NCT01630187	Phase 4	Carbetocin
48	Effect of Metformin With or Without Folate Addiction on Uterine Blood Flow and Trophoblastic Invasion in Pregnant Patients With Polycystic Ovary Syndrome	Completed	NCT01115140	Phase 4	metformin plus placebo;Metformin plus folic acid;placebo plus folic acid;placebo alone
49	Effects of Tranexamic Acid on Post Partum Hemorrhage by Uterine Atony After Cesarean Section Delivery: a Randomized, Placebo Controlled Trial.	Completed	NCT01599468	Phase 4	Tranexamic Acid;saline serum
50	Pilot of Letrozole for Uterine Myomas	Completed	NCT02470741	Phase 4	Letrozole

Search NIH Clinical Center for Uterine Anomalies

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

CARBOXYMETHYLCELLULOSE CALCIUM

Cochrane evidence based reviews: uterine diseases

Sources

Genetic Tests for Uterine Anomalies

Sources

Anatomical Context for Uterine Anomalies

Organs/tissues related to Uterine Anomalies:

FMA: Uterus

MalaCards : Uterus, Cervix, Lymph Node, Thyroid, Breast, Placenta, Bone Marrow

Sources

Publications for Uterine Anomalies

Articles related to Uterine Anomalies:

(show top 50) (show all 1357)

#	Title	Authors	PMID	Year
1	Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer. ⁶² ⁴¹	Ryu KJ...Park H	36441547	2022
2	Androgen Signaling in Uterine Diseases: New Insights and New Targets. ⁶² ⁴¹	Lv M...Liao H	36358974	2022
3	Familial bicornuate and double uterus. ⁵⁷	Polishuk WZ...Ron MA	4841581	1974
4	[On the problem of frequent familial occurrence of uterus abnormalities]. ⁵⁷	Drescher H	5997716	1966
5	Observations on the results of pregnancies in women resident in Belfast. II. Abortions, hydatidiform moles and ectopic pregnancies. ⁵⁷	STEVENSON AC...McCLURE HI	13834545	1959
6	Congenital abnormalities of the uterus and pregnancy. ⁵⁷	HOLMES JA	13316096	1956
7	UTERUS DIDELPHYS. ⁵⁷	Nykiforuk NE	20320870	1938
8	The link between intrauterine adhesions and impaired reproductive performance: a systematic review of the literature. ⁴¹	Hooker AB...Huirne JAF	36376829	2022
9	Oestrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. ⁵³ ⁶²	Kitawaki J...Honjo H	11139535	2001
10	ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function. ⁵³ ⁶²	Ricci MS...Toscano WA	10478797	1999
11	Expression of estrogen receptor variants in normal and neoplastic human uterus. ⁵³ ⁶²	Hu C...Baker VV	8735603	1996
12	Surgical management of a congenital genital tract abnormality in a patient with Lynch syndrome. ⁶²	Olayato-Aribo E...Underwood T	36460312	2022
13	Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? Evidence-based recommendations for clinical use. ⁶²	Conde-Agudelo A...Romero R	36475431	2022
14	Use of Two Levonorgestrel Intrauterine Devices in a Patient with a Uterus Didelphys: A Case Report. ⁶²	O'Brien K...Rosen MW	35820604	2022
15	The association between congenital uterine anomalies and perinatal outcomes - does type of defect matters? ⁶²	Naeh A...Gabbay-Benziv R	34238096	2022
16	Evaluation of complications, conversion rate, malignancy rate, and, surgeon's experience in laparoscopic assisted supracervical hysterectomy (LASH) of 1274 large uteri: A retrospective study. ⁶²	Tchartchian G...De Wilde RL	36203317	2022
17	In vitro effects of cinnamon, oregano, and thyme essential oils against Escherichia coli and Trueperella pyogenes isolated from dairy cows with clinical endometritis. ⁶²	Paiano RB...Moreno AM	36413866	2022
18	Role of Genital Tract Bacteria in Promoting Endometrial Health in Cattle. ⁶²	Adnane M...Chapwanya A	36422307	2022
19	Pegbovigrastim treatment resulted in an economic benefit in a large randomized clinical trial in grazing dairy cows. ⁶²	Barca J...Hogeveen H	36460504	2022
20	Prepartum heat stress in dairy cows increases postpartum inflammatory responses in blood of lactating dairy cows. ⁶²	Molinari PCC...Bromfield JJ	36460497	2022
21	Intrauterine infusion of a pathogenic bacterial cocktail is associated with the development of clinical metritis in postpartum multiparous Holstein cows. ⁶²	Silva JCC...Bicalho RC	36400620	2022
22	Effect of VD3 on cell proliferation and the Wnt signaling pathway in bovine endometrial epithelial cells treated with lipopolysaccharide. ⁶²	Zhang F...Zhang Z	36156426	2022
23	Hysteroscopicmetroplasty as a treatment option for women with congenital dysmorphic uterus suffering from impaired reproductive performance. ⁶²	Cohen SB...Burke YZ	36377644	2022
24	Limitations of imaging screening tests in the detection of incomplete uterine septum or arcuate uterine anomaly. ⁶²	Yousif A...Abuzeid MI	35315517	2022
25	CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. ⁶²	Shawn LyBarger K...Frieboes HB	36396713	2022
26	Current chemotherapeutic options for the treatment of gestational trophoblastic disease. ⁶²	Braga A...Berkowitz RS	36399723	2022
27	Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology. ⁶²	Guo SW	36099328	2022
28	Study on Preoperative Neutrophil/Lymphocyte (NLR) and Platelet/Lymphocyte Ratio (PLR) as a Predictive Factor in Endometrial Cancer. ⁶²	Muangto T...Suwannarurk K	36308354	2022
29	Prevalence of subclinical endometritis in dairy cows that recovered after treatment of clinical endometritis with cephapirin and PGF2α. ⁶²	Baranski W...Janowski T	36108547	2022
30	Reproductive and ICSI outcomes after hysteroscopic metroplasty for T-shaped uterus, a prospective follow up study. ⁶²	Acet F...Tavmergen E	35914707	2022
31	Transient non-cyclical activity of external myometrium should be considered to avoid errors in diagnosis of adenomyosis and uterine anomalies. ⁶²	Puente JM...Garcia-Velasco JA	34985801	2022
32	The effect of hysteroscopic metroplasty on fertility in T-shaped and Y-shaped dysmorphic uterus. ⁶²	Dilbaz B...Ustun YE	35727192	2022
33	What type of uterine anomalies had an additional effect on pregnancy outcomes, compared to other uterine anomalies? An evaluation of a large population database. ⁶²	Kadour Peero E...Dahan MH	36216352	2022
34	Research on acute phase proteins and inflammatory cytokines biomarkers in dromedary camels (Camelus dromedarius) with clinical endometritis. ⁶²	El-Deeb W...Fayez M	36282373	2022
35	Effect of calving season on metritis incidence and bacterial content of the vagina in dairy cows. ⁶²	Molinari PCC...Bromfield JJ	35970030	2022
36	Long-term Experience of Single-port and Multi-port Total Laparoscopic Hysterectomy in a Single Center. ⁶²	Lee J...Hong DG	36099098	2022
37	Factors Associated with the Severity of Clinical Mastitis. ⁶²	Fredebeul-Krein F...Kromker V	36297146	2022
38	Icariin Alleviates Escherichia coli Lipopolysaccharide-Mediated Endometritis in Mice by Inhibiting Inflammation and Oxidative Stress. ⁶²	Shaukat A...Yang L	36142129	2022
39	Effectiveness of a Modified Administration Protocol for the Medical Treatment of Feline Pyometra. ⁶²	Attard S...Pisu MC	36288130	2022
40	Progesterone supplementation to improve fertility of selected subgroups of lactating cows during the summer and fall. ⁶²	Roth Z...Wolfenson D	35582955	2022
41	Accuracy to Predict the Onset of Calving in Dairy Farms by Using Different Precision Livestock Farming Devices. ⁶²	Szenci O	35953995	2022
42	Staphylococcus aureus-Induced Necroptosis Promotes Mitochondrial Damage in Goat Endometrial Epithelial Cells. ⁶²	Yi Y...Jin Y	36077938	2022
43	How do bicornuate uteri alter pregnancy, intra-partum and neonatal risks? A population based study of more than three million deliveries and more than 6000 bicornuate uteri. ⁶²	Kadour Peero E...Dahan MH	35946504	2022
44	A Comparative Analysis of Nondescent Vaginal Hysterectomy, Laparoscopy-Assisted Vaginal Hysterectomy, and Total Laparoscopic Hysterectomy for Benign Uterine Diseases at a Rural Tertiary Care Center. ⁶²	Kanti V...Singh NP	36158288	2022
45	Preliminary application of three-dimensional printing in congenital uterine anomalies based on three-dimensional transvaginal ultrasonographic data. ⁶²	Wang L...Zhang L	35836228	2022
46	Surgical disorders in pediatric and adolescent gynecology: Vaginal and uterine anomalies. ⁶²	Mentessidou A...Mirilas P	35880405	2022
47	Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma. ⁶²	Smith ES...Leitao MM	35641004	2022
48	Peroxisome proliferator-activated receptor expression in the canine endometrium with cystic endometrial hyperplasia-pyometra complex. ⁶²	Socha BM...Skarzynski DJ	35373395	2022
49	Quantitative assessment of iteratively denoised 3D SPACE with inner-volume excitation and simultaneous multi-slice BLADE for optimizing female pelvis magnetic resonance imaging at 1.5 T. ⁶²	Hausmann D...Kubik-Huch RA	35871059	2022
50	First report on clinical aspects, blood profiles, bacterial isolation, antimicrobial susceptibility, and histopathology in canine pyometra in Thailand. ⁶²	Lansubsakul N...Limmanont C	36185522	2022

Sources

Genes for Uterine Anomalies

Genes related to Uterine Anomalies (0 elite genes):

(show top 50) (show all 105)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR199A1	MicroRNA 199a-1	RNA Gene	15.05	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
2	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	13.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17010061 19717534
3	HNF1B	HNF1 Homeobox B	Protein Coding	13.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15930087
4	ESR1	Estrogen Receptor 1	Protein Coding	13.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8735603 10478797 11139535
5	MIR518D	MicroRNA 518d	RNA Gene	12.13	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
6	MIR21	MicroRNA 21	RNA Gene	11.82	DISEASES inferred ¹⁴ ¹⁴
7	MIR145	MicroRNA 145	RNA Gene	11.42	DISEASES inferred ¹⁴ ¹⁴
8	MIR139	MicroRNA 139	RNA Gene	11.32	DISEASES inferred ¹⁴ ¹⁴
9	H2AC18	H2A Clustered Histone 18	Protein Coding	11.31	DISEASES inferred ¹⁴ ¹⁴
10	MIR143	MicroRNA 143	RNA Gene	11.29	DISEASES inferred ¹⁴ ¹⁴
11	MIR196A1	MicroRNA 196a-1	RNA Gene	11.21	DISEASES inferred ¹⁴ ¹⁴
12	MIR141	MicroRNA 141	RNA Gene	11.14	DISEASES inferred ¹⁴ ¹⁴
13	MIR17	MicroRNA 17	RNA Gene	11.09	DISEASES inferred ¹⁴ ¹⁴
14	MIR200A	MicroRNA 200a	RNA Gene	11.02	DISEASES inferred ¹⁴ ¹⁴
15	MIR361	MicroRNA 361	RNA Gene	10.98	DISEASES inferred ¹⁴ ¹⁴
16	MIR34A	MicroRNA 34a	RNA Gene	10.96	DISEASES inferred ¹⁴ ¹⁴
17	MIR518A1	MicroRNA 518a-1	RNA Gene	10.95	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
18	MIR214	MicroRNA 214	RNA Gene	10.91	DISEASES inferred ¹⁴ ¹⁴
19	MIR142	MicroRNA 142	RNA Gene	10.8	DISEASES inferred ¹⁴ ¹⁴
20	MIR9-1	MicroRNA 9-1	RNA Gene	10.66	DISEASES inferred ¹⁴ ¹⁴
21	MIR193A	MicroRNA 193a	RNA Gene	10.65	DISEASES inferred ¹⁴ ¹⁴
22	MIR126	MicroRNA 126	RNA Gene	10.59	DISEASES inferred ¹⁴ ¹⁴
23	MIR30A	MicroRNA 30a	RNA Gene	10.58	DISEASES inferred ¹⁴ ¹⁴
24	MIR27A	MicroRNA 27a	RNA Gene	10.57	DISEASES inferred ¹⁴ ¹⁴
25	MIR140	MicroRNA 140	RNA Gene	10.52	DISEASES inferred ¹⁴ ¹⁴
26	MIR101-1	MicroRNA 101-1	RNA Gene	10.52	DISEASES inferred ¹⁴ ¹⁴
27	MIR125A	MicroRNA 125a	RNA Gene	10.5	DISEASES inferred ¹⁴ ¹⁴
28	MIR31	MicroRNA 31	RNA Gene	10.46	DISEASES inferred ¹⁴ ¹⁴
29	MIR204	MicroRNA 204	RNA Gene	10.43	DISEASES inferred ¹⁴ ¹⁴
30	MIR195	MicroRNA 195	RNA Gene	10.43	DISEASES inferred ¹⁴ ¹⁴
31	MIR149	MicroRNA 149	RNA Gene	10.37	DISEASES inferred ¹⁴ ¹⁴
32	MIR146A	MicroRNA 146a	RNA Gene	10.36	DISEASES inferred ¹⁴ ¹⁴
33	MIR93	MicroRNA 93	RNA Gene	10.32	DISEASES inferred ¹⁴ ¹⁴
34	MIR200C	MicroRNA 200c	RNA Gene	10.31	DISEASES inferred ¹⁴ ¹⁴
35	MIR200B	MicroRNA 200b	RNA Gene	10.3	DISEASES inferred ¹⁴ ¹⁴
36	MIR221	MicroRNA 221	RNA Gene	10.29	DISEASES inferred ¹⁴ ¹⁴
37	MIR590	MicroRNA 590	RNA Gene	10.28	DISEASES inferred ¹⁴ ¹⁴
38	MIR15A	MicroRNA 15a	RNA Gene	10.27	DISEASES inferred ¹⁴ ¹⁴
39	MIR423	MicroRNA 423	RNA Gene	10.25	DISEASES inferred ¹⁴ ¹⁴
40	MIR486-1	MicroRNA 486-1	RNA Gene	10.24	DISEASES inferred ¹⁴ ¹⁴
41	MIR186	MicroRNA 186	RNA Gene	10.23	DISEASES inferred ¹⁴ ¹⁴
42	MIR130B	MicroRNA 130b	RNA Gene	10.2	DISEASES inferred ¹⁴ ¹⁴
43	MIR224	MicroRNA 224	RNA Gene	10.2	DISEASES inferred ¹⁴ ¹⁴
44	MIR205	MicroRNA 205	RNA Gene	10.18	DISEASES inferred ¹⁴ ¹⁴
45	MIR34C	MicroRNA 34c	RNA Gene	10.1	DISEASES inferred ¹⁴ ¹⁴
46	MIR155	MicroRNA 155	RNA Gene	10.09	DISEASES inferred ¹⁴ ¹⁴
47	MIR144	MicroRNA 144	RNA Gene	10.07	DISEASES inferred ¹⁴ ¹⁴
48	MIR210	MicroRNA 210	RNA Gene	10.05	DISEASES inferred ¹⁴ ¹⁴
49	MIR338	MicroRNA 338	RNA Gene	10.01	DISEASES inferred ¹⁴ ¹⁴
50	MIR330	MicroRNA 330	RNA Gene	9.99	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Uterine Anomalies

Sources

Expression for Uterine Anomalies

Search GEO for disease gene expression data for Uterine Anomalies.

Sources

Pathways for Uterine Anomalies

Pathways related to Uterine Anomalies according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	11.28	MIR21 MIR17 MIR145 MIR143
2	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.18	MIR34A MIR214 MIR21
3	miRNAs involvement in the immune response in sepsis ⁷⁴	11.05	MIR9-1 MIR21 MIR199A1 MIR145
4	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11	MIR9-1 MIR214 MIR199A1 MIR17 MIR145 MIR143
5	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.62	MIR21 MIR200A
6	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶⁰	9.86	ESR1 CYP19A1

Sources

GO Terms for Uterine Anomalies

Cellular components related to Uterine Anomalies according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.74	MIR9-1 MIR361 MIR214 MIR21 MIR200A MIR199A1
2	extracellular vesicle	GO:1903561	9.26	MIR34A MIR214 MIR21 MIR17

Biological processes related to Uterine Anomalies according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.92	ESR1 MIR17 MIR199A1 MIR21 MIR214 MIR34A
2	negative regulation of inflammatory response	GO:0050728	9.87	MIR199A1 MIR145 MIR142 MIR141
3	negative regulation of cell migration	GO:0030336	9.85	MIR9-1 MIR34A MIR214 MIR21 MIR145
4	miRNA-mediated gene silencing	GO:0035195	9.8	MIR139 MIR141 MIR142 MIR143 MIR145 MIR17
5	negative regulation of osteoblast differentiation	GO:0045668	9.79	MIR9-1 MIR214 MIR17
6	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.78	MIR214 MIR21 MIR17
7	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.72	MIR361 MIR199A1 MIR196A1
8	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.71	MIR145 MIR199A1 MIR21
9	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.71	MIR9-1 MIR21 MIR17 MIR145
10	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.65	MIR34A MIR214 MIR21
11	negative regulation of angiogenesis	GO:0016525	9.63	MIR361 MIR34A MIR214 MIR21 MIR145 MIR143
12	angiotensin-activated signaling pathway	GO:0038166	9.62	MIR145 MIR143
13	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.6	MIR21 MIR17
14	aorta smooth muscle tissue morphogenesis	GO:0060414	9.59	MIR145 MIR143
15	negative regulation of lamellipodium assembly	GO:0010593	9.58	MIR214 MIR196A1
16	positive regulation of metalloendopeptidase activity	GO:1904685	9.58	MIR21 MIR17
17	negative regulation of BMP secretion	GO:2001285	9.56	MIR214 MIR17
18	positive regulation of connective tissue replacement	GO:1905205	9.54	MIR34A MIR214 MIR199A1
19	regulation of phenotypic switching	GO:1900239	9.52	MIR145 MIR143
20	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.51	MIR17 MIR143
21	positive regulation of cellular response to hypoxia	GO:1900039	9.49	MIR21 MIR145
22	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.43	MIR145 MIR143
23	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.43	MIR214 MIR199A1 MIR17
24	negative regulation of vascular endothelial growth factor production	GO:1904046	9.26	MIR361 MIR34A MIR199A1 MIR17

Molecular functions related to Uterine Anomalies according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.73	MIR9-1 MIR361 MIR34A MIR214 MIR21 MIR199A1
2	mRNA base-pairing translational repressor activity	GO:1903231	9.5	MIR9-1 MIR518A1 MIR361 MIR34A MIR214 MIR21